PITTSBURGH (August 7, 2017) …The University of Pittsburgh Coulter Translational Research Partners II Program awarded grants totaling $650,000 to six translational research teams through its most recent funding cycle. The new funded projects include a biomarker for identifying intracranial hemorrhage, a biosensor platform for detecting cardiac events, a drug
delivery platform for preventing sexually transmitted infections, a device to improve viability of donor livers for transplantation, a novel peripheral IV placement catheter, and a significantly improved surgical retractor.
“The six winning teams met our rigorous business oriented criteria and were among the best we have seen. They were also among the most diverse, as a result of a broader field of applicants,” said Max Fedor, Coulter Program Director. “In addition to direct funding for translational research, teams receive significant coaching from our experienced staff and from external business and clinical experts, who have partnered
with us. We are extremely pleased with the success of this year’s program and look forward to expanding further funding collaborations across the University community in the upcoming competitive grant cycle this fall.” The Coulter Program,
housed within Pitt’s Department of Bioengineering, is a partnership between the Swanson School of Engineering, the Schools of the Health Sciences and the Innovation Institute. The Program aims to identify, select, and develop promising late-stage
biomedical projects that address significant unmet clinical needs and have the potential for positive clinical and economic impacts.
The 2017 Coulter funding cycle was unique from previous years, in that applications were accepted in collaboration with the Center for Commercial Applications of Healthcare Data and SciVelo, the Department of Dermatology, the Department of Plastic Surgery,
the Magee-Womens Research Institute, the Pittsburgh Liver Research Center, the University of Pittsburgh Cancer Institute, and the Vascular Medicine Institute. Each partner agreed to provide financial support jointly with Coulter for winning projects
within their category. Details on the six funded technologies and their scientific and clinical teams include:
Biomarkers for Infant Brain Injury Score (BIBIS): A serum biomarker panel for improving identification of intracranial hemorrhage in infants and young children.
CardioSense: A universal biosensor platform for detection and monitoring of congestive heart failure and myocardial infarction.
HerShield: A quick dissolving vaginal film for on-demand drug delivery platform for protection against sexually transmitted infections.
OrganEvac: A whole-organ sonothrombolysis device to increase the number of livers available for transplantation from donors after cardiac death
ThreadRite IV: A novel resistance-sensing catheter with guidewire to expedite peripheral IV placement on the first attempt.
Steeltown Retractor: A flexible arm surgical tool holder that gives surgeons unprecedented fast, precise tool positioning capabilities while minimizing operating room (OR) costs for the hospital
About the Coulter Translational Research Partners II ProgramThe Coulter Translational Research Partners II Program is a University based accelerator, designed to help faculty researchers translate their innovations to commercialization.
By way of a competitive grant program, training processes, and collaborative services, our goal is to de-risk University technology and identify viable commercial pathways through the complex healthcare industry landscape. Further, we engage extensively
with business partners, mentors and clinical experts to bring industry perspectives to translational research. In 6 years, the Coulter Program has attracted almost 200 applications, funded 31 projects leading to eight license agreements, four optioned
technologies and eight start-up companies.
Contact: Paul Kovach